Covance R&D Deal Meshes With Lilly’s “FIPNet” Model
Executive Summary
Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance
You may also be interested in...
Should Big Pharma Redirect Resources From Early R&D?
With pharma under pressure from patent expirations and lack of innovative new products, research productivity is a hot button issue. Large drug companies increasingly rely on external sources to fill pipelines, but some industry observers say they're not going far enough.
Should Big Pharma Redirect Resources From Early R&D?
With pharma under pressure from patent expirations and lack of innovative new products, research productivity is a hot button issue. Large drug companies increasingly rely on external sources to fill pipelines, but some industry observers say they're not going far enough.
Asset Finance Funds Aim for Pharma Cash, Partnerships
Like many of its drug-industry brethren, Bayer Healthcare AG says it's ready to find good homes for the drug candidates it can't develop itself